Subscribe
unusedbrandon-bourdages-shutterstock-com-us-supreme-court--1
Brandon Bourdages / Shutterstock.com
5 December 2016Americas

Life Technologies v Promega to be heard at US Supreme Court

Oral arguments in Life Technologies v Promega are due to take place tomorrow in the US Supreme Court to determine whether the US Court of Appeals for the Federal Circuit correctly defined “substantial portion”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
SCOTUS reverses Federal Circuit in Life Technologies v Promega
22 February 2017   The US Supreme Court today ruled that supplying a single component of a multi-component invention for manufacture abroad does not constitute patent infringement.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Americas
SCOTUS reverses Federal Circuit in Life Technologies v Promega
22 February 2017   The US Supreme Court today ruled that supplying a single component of a multi-component invention for manufacture abroad does not constitute patent infringement.

More on this story

Americas
SCOTUS reverses Federal Circuit in Life Technologies v Promega
22 February 2017   The US Supreme Court today ruled that supplying a single component of a multi-component invention for manufacture abroad does not constitute patent infringement.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York